Trial reportThorax1994
Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.
Trial report in Thorax, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2006Guideline
- Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis.The Cochrane database of systematic reviews · 2000Pooled it
- Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.Paediatric drugs · 2017Review
- Prevention and treatment of systemic glucocorticoid side effects.International journal of dermatology · 2010Review
- Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options.Drug, healthcare and patient safety · 2010Article
- Glucocorticoid-induced osteoporosis.Current osteoporosis reports · 2009Review
- Medication-induced osteoporosis.Current osteoporosis reports · 2007Review
- Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.Clinical rheumatology · 2007Review
- 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2002Review
- Corticosteroid-Induced osteoporosis: detection and management.Drug safety · 2001Review
- Corticosteroid-induced bone loss. Prevention and management.Drug safety · 1996Review
- Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 1996Review
- Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.BMJ (Clinical research ed.) · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInjectable calcitonin is effective in reducing spinal bone loss in steroid-dependent asthma but side effects are frequent. In contrast, a nasal spray presentation has been shown to be effective and well tolerated in involutional osteoporosis. To test the efficacy of nasal calcitonin a two year prospective trial was conducted in 44 steroid-dependent asthmatic patients.
methodsAll patients received a calcium supplement of 1000 mg and were allocated randomly into two groups treated with either salmon calcitonin nasal spray (200 IU every other day, n = 22) or calcium alone (n = 22) for two years. All patients completed the first year of the study. Five patients in each group dropped out during the second year. In the calcitonin group one patient developed generalised pruritus and four lost steroid dependence, and in the calcium alone group five were no longer dependent on steroids. The efficacy of treatment was evaluated as follows: bone turnover assessed by biochemical markers, bone loss assessed by serial measurement of lumbar spine density, and rates of bone fractures.
resultsThe bone mass in the calcitonin group increased by 2.7% in the first year while in the group receiving calcium alone it decreased by 2.8%; this difference was significant. Calcitonin prevented more bone loss during the second year while the calcium alone group continued losing bone mass (-7.8%). The difference between means was 0.1077 (95% CI 0.0381 to 0.1773). Three new fractures occurred in both groups. No changes in biochemical parameters were detected in either group.
conclusionsCalcitonin given intranasally increased spinal bone mass during the first year of treatment and maintained bone mass in a steady state during the second year. These results suggest that calcitonin may be a useful agent to prevent steroid-induced osteoporosis. However, the lack of effect of calcitonin on the rate of vertebral fractures does not permit its recommendation for routine use in preventing steroid-induced osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.